{"id":"purified-vero-rabies-vaccine","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Injection site pain, erythema, or swelling"},{"rate":"10-20","effect":"Headache"},{"rate":"5-15","effect":"Myalgia or arthralgia"},{"rate":"5-10","effect":"Fever"},{"rate":"5-10","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL2107909","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine is produced in Vero cells (monkey kidney cells) and contains inactivated rabies virus antigen. Upon administration, it triggers both humoral (antibody) and cell-mediated immune responses that provide protection against rabies virus infection. The immune response generates neutralizing antibodies that prevent viral entry and spread, providing post-exposure and pre-exposure prophylaxis.","oneSentence":"Purified Vero Rabies Vaccine stimulates the immune system to produce antibodies and cellular immunity against rabies virus by presenting inactivated rabies antigen.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:42.789Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rabies post-exposure prophylaxis (PEP) in previously unvaccinated individuals"},{"name":"Rabies pre-exposure prophylaxis (PrEP) in high-risk populations"},{"name":"Rabies booster vaccination in previously vaccinated individuals"}]},"trialDetails":[{"nctId":"NCT07183371","phase":"PHASE2","title":"A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2025-12-15","conditions":"Malaria,Falciparum","enrollment":360},{"nctId":"NCT04127786","phase":"PHASE3","title":"Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-10-21","conditions":"Rabies, Healthy Volunteers","enrollment":1708},{"nctId":"NCT07147400","phase":"PHASE2","title":"Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults","status":"RECRUITING","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2025-08-22","conditions":"Prevention of Malaria Transmission and Clinical Malaria","enrollment":1200},{"nctId":"NCT04478084","phase":"PHASE3","title":"Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adult and Pediatric Population in Thaïland","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-08-04","conditions":"Rabies (Healthy Volunteers)","enrollment":403},{"nctId":"NCT04594551","phase":"PHASE3","title":"Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adults in Thaïland","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-10-11","conditions":"Rabies (Healthy Volunteers)","enrollment":201},{"nctId":"NCT03965962","phase":"PHASE3","title":"Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-07-01","conditions":"Rabies (Healthy Volunteers)","enrollment":640},{"nctId":"NCT05846568","phase":"PHASE3","title":"Study to Evaluate GR1801's Efficacy and Safety","status":"COMPLETED","sponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","startDate":"2022-10-21","conditions":"Rabies Post-exposure Prophylaxis","enrollment":1200},{"nctId":"NCT06433440","phase":"PHASE4","title":"Safety and Immunogenicity of Purified Verocell Rabies Vaccine PVRV Administered Intramuscularly and Intradermally","status":"COMPLETED","sponsor":"University of Peshawar","startDate":"2020-07-01","conditions":"Rabies","enrollment":100},{"nctId":"NCT05135273","phase":"PHASE1","title":"Study of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Malaria in Adults in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-10-22","conditions":"Malaria,Falciparum","enrollment":80},{"nctId":"NCT05937113","phase":"PHASE4","title":"Safety and Immunogenicity of the Inactivated Rabies Vaccine RABIVAX-S Administered Intramuscularly and Intradermally","status":"COMPLETED","sponsor":"Vietnam Military Medical University","startDate":"2020-06-13","conditions":"Rabies","enrollment":220},{"nctId":"NCT04644484","phase":"PHASE3","title":"A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety","status":"COMPLETED","sponsor":"Synermore Biologics (Suzhou) Co., Ltd.","startDate":"2020-09-23","conditions":"Rabies, Communicable Disease, Virus Diseases","enrollment":1000},{"nctId":"NCT03700242","phase":"PHASE3","title":"Imovax® Rabies and VERORAB® Immunogenicity and Safety After One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Post-Exposure Prophylaxis Regimen at One Year","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-09-26","conditions":"Healthy Volunteers (Rabies Immunization)","enrollment":570},{"nctId":"NCT03145766","phase":"PHASE2","title":"Immunogenicity and Safety of a Purified Vero Rabies Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2017-04-17","conditions":"Rabies Virus","enrollment":320},{"nctId":"NCT03656198","phase":"PHASE4","title":"Non-specific Effects of Rabies Vaccine","status":"COMPLETED","sponsor":"Ross University School of Veterinary Medicine","startDate":"2018-08-29","conditions":"Influenza-like Illness, Upper Respiratory Disease, Diarrhea","enrollment":546},{"nctId":"NCT03741270","phase":"PHASE4","title":"Safety of Rabivax-S for Pre-exposure Prophylaxis","status":"COMPLETED","sponsor":"Ross University School of Veterinary Medicine","startDate":"2018-10-24","conditions":"Rabies Vaccine Adverse Reaction","enrollment":159},{"nctId":"NCT01148459","phase":"PHASE3","title":"Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-30","conditions":"Malaria","enrollment":200},{"nctId":"NCT01137045","phase":"PHASE4","title":"Immunogenicity and Safety Study of A New Chromatographically Purified Vero Cell Rabies Vaccine With ID Regimen and ERIG","status":"COMPLETED","sponsor":"Queen Saovabha Memorial Institute","startDate":"2010-06","conditions":"Rabies","enrollment":210},{"nctId":"NCT01784874","phase":"PHASE2","title":"Comparison of Purified Vero Rabies Vaccine, Serum Free With Human Diploid Cell Vaccine in Pre-exposure Use","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-02","conditions":"Rabies","enrollment":408},{"nctId":"NCT01930357","phase":"PHASE2","title":"Purified Vero Rabies Vaccine-Serum Free Compared to Human Diploid Cell Vaccine in a Pre-exposure Prophylaxis Regimen","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-09","conditions":"Rabies","enrollment":342},{"nctId":"NCT02490956","phase":"PHASE4","title":"Diagnostic Immunization With Rabies Vaccine in Patients With PID","status":"UNKNOWN","sponsor":"Chulalongkorn University","startDate":"2015-04","conditions":"Primary Immunodeficiency","enrollment":40},{"nctId":"NCT02339896","phase":"","title":"Observation Study an Immunogenicity Modified TRC-ID Regimen With CPRV With or Without Rabies Immunoglobulin in Children","status":"UNKNOWN","sponsor":"Queen Saovabha Memorial Institute","startDate":"2014-02","conditions":"Dog Bite","enrollment":45},{"nctId":"NCT01877395","phase":"PHASE2","title":"Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-06","conditions":"Rabies","enrollment":342},{"nctId":"NCT00948272","phase":"PHASE2","title":"Study of Purified Vero Rabies Vaccine Serum Free Compared With Reference Purified Vero Rabies Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-07","conditions":"Rabies","enrollment":384},{"nctId":"NCT01339312","phase":"PHASE3","title":"Study of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-04","conditions":"Rabies, Rabies Virus","enrollment":816},{"nctId":"NCT01810731","phase":"PHASE2, PHASE3","title":"Safety and Immunogenicity Study of Influenza Vaccines in HIV-infected and HIV-uninfected Pregnant Women in Western Kenya","status":"WITHDRAWN","sponsor":"Centers for Disease Control and Prevention","startDate":"2014-04","conditions":"Influenza, Human, HIV, Malaria","enrollment":""},{"nctId":"NCT01603875","phase":"NA","title":"Immune Response in Adults to PrEP and Simulated Booster PEP With a New CPRV","status":"COMPLETED","sponsor":"Queen Saovabha Memorial Institute","startDate":"2012-07","conditions":"Efficacy of the New CPRV","enrollment":105},{"nctId":"NCT00260351","phase":"PHASE4","title":"Immunogenicity and Safety of Verorab™ in Indian Population","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2004-12","conditions":"Rabies","enrollment":405},{"nctId":"NCT01228383","phase":"PHASE2","title":"Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2011-12","conditions":"Rabies","enrollment":240}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Verorab Vaccine"],"phase":"phase_3","status":"active","brandName":"Purified Vero Rabies Vaccine","genericName":"Purified Vero Rabies Vaccine","companyName":"Sanofi Pasteur, a Sanofi Company","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"Purified Vero Rabies Vaccine stimulates the immune system to produce antibodies and cellular immunity against rabies virus by presenting inactivated rabies antigen. Used for Rabies post-exposure prophylaxis (PEP) in previously unvaccinated individuals, Rabies pre-exposure prophylaxis (PrEP) in high-risk populations, Rabies booster vaccination in previously vaccinated individuals.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}